

## ERYTECH to present at upcoming investor conferences

**Lyon (France), May 20, 2013** – ERYTECH (Euronext Paris: ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukaemia and other oncology indications with unmet medical needs, announced today that in May and June the company will present at several visible investor events in Europe and the U.S following its successful IPO on April, 2013. As a public company ERYTECH is committed to actively engage with investors and the financial community.

May 22, 2013

**BioEquity Europe 2013**, Sheraton Stockholm, Sweden

Attendee: Gil Beyen, Chairman & CEO

May 23, 2013

**Midcap Healthcare Forum Gilbert Dupont**, Chateauform' – Parc Monceau, Paris, France

Presenters: Gil Beyen, Chairman & CEO and Pierre-Olivier Goineau, Vice President & COO

June 11-12

**BOSTON CEO Event**, Four Seasons Hotel, Boston, U.S.

Attendee: Gil Beyen, Chairman & CEO

**About ERYTECH:** [www.erytech.com](http://www.erytech.com)

Created in Lyon in 2004, ERYTECH is a French biopharmaceuticals company that opens new prospects for cancer patients, particularly those with acute leukaemia. By encapsulating the asparaginase enzyme in red blood cells, ERYTECH has developed GRASPA<sup>®</sup>, an original and effective treatment that targets leukaemia cells through “starvation” while significantly reducing the side effects for patients. GRASPA<sup>®</sup> is currently completing Phase III clinical development in Acute Lymphoblastic Leukemia (ALL) and is in Phase II clinical trial in Acute Myeloid Leukemia (AML). ERYTECH has concluded distribution partnership agreements for Europe with the Recordati-Orphan Europe group, and with TEVA for Israël. In the United States, ERYTECH is launching a Phase I clinical trial in ALL, after having received approval from the US FDA..

### CONTACTS

#### ERYTECH

#### Gil Beyen

*Chairman and CEO*

#### Pierre-Olivier Goineau

*Vice President and COO*

Tel: +33 4 78 74 44 38

[investors@erytech.com](mailto:investors@erytech.com)

#### NewCap.

Investor and press relations

#### Julien Perez / Emmanuel Huynh

Tel: +33 1 44 71 98 52

[erytech@newcap.fr](mailto:erytech@newcap.fr)